ScinoPharm

1789 TT

ScinoPharm Management Presentation

2017 JP Morgan Healthcare Conference

January 11, 2017

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm's **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Table of Content

- Overview of ScinoPharm
- ScinoPharm's Strategies and Opportunities
  - Formulation Business
  - China Market
- Operating Results & Outlook

Overview of ScinoPharm

Background

- Company specializes in high potency (steroid/cytotoxic) APIs and is expanding into sterile/aseptic injectable formulations
- Facility & organization established in Taiwan and expanding in China with a new GMP plant in Changshu & marketing base in Shanghai
- 72 generic APIs in current portfolio with 25 APIs launched; 53 US DMFs filed (752 DMFs WW), 32 US DMFs in oncology APIs. 100+ NCE CRAM projects, with 5 APIs launched and 5 in phase III for NDA filing in 1-3 years
- Fully compliant with world-class cGMPs and international regulatory requirements; Certified by US FDA, EMA, EDQM, Australian TGA, Japanese PMDA

World Class API Facilities

Taiwan

- 6.6 hectares of land, 330K sq.ft. facilities with >200M^3 reactor volume
- 5 of 16 production lines equipped with high potency capabilities for cytotoxic/steroids
- Passed US FDA, EMA, EDQM, Australian TGA, Japanese PMDA inspections, & 300+ cGMP customer audits
- Provides comprehensive contract research & manufacturing services for brand drug companies
- Global Market

China

- 6.7 hectares of land with > 250M^3 reactor volume
- 3 of 7 production lines equipped with high potency capabilities for cytotoxics
- US FDA approved cGMP facility for intermediates & high potency API
- Full scope capabilities in the development and production of APIs on small to large scales for generic & CRAM markets
- Global market including China

Strong Generics Product Portfolio



Note: Other (Women's Health, Gastrointestinal, Immunology and Metabolic)

ScinoPharm

Diversified CRAM Portfolio

* Already Filed

Stage	First Launch Year	Indication	Market(s)
Commercial	2005	Eluting Stent	US
Commercial	2009/2013	Skin Infection/HAP	US/EU
Commercial	2011	Depression	US
Commercial	2012	Obesity	US
Commercial	2013	Seizure	US
Stage	**Est. NDA Filing Year**	**Indication**	**Market(s)**
Phase III	2016*	Infectious Disease	US / EU / Asia
Phase III	2017	Ovarian Cancer	US / EU
Phase III	2017	Prostate Cancer	US
Phase III	2017	Ovarian Cancer	CN
Phase III	2018	Parkinson's Disease	US

ScinoPharm - Oncology API Leader





Source: USFDA DMF Q3 2016 database

ScinoPharm

2016 Sales Distribution

By Business



By Indication



By Region



ScinoPharm

ScinoPharm's

Strategies and Opportunities

We are Transforming our Company



ScinoPharm

Keys to Generic Formulation Business

Opportunity	Strategy	Tactics
✓ Already the leader in providing oncology APIs to regulated markets worldwide ✓ Injectable CMOs are in short supply ✓ Can be customer's injectables provider by developing formulations using our own oncology APIs or others' APIs, up to and including ANDA filing with FDA	✓ Developing dossiers per our difficult-to-make APIs to increase value proposition in the supply chain ✓ Targeted delivery & extended release of proven APIs via 505(b)(2) fast track ✓ Collaborating with start-ups & research institutes, focusing on un-met oncology medical needs of high prevalence in Asia	✓ Expanding formulation portfolio ✓ Establishing on-site oncology injectable facility and providing an integrated supply chain ✓ Promoting our formulations via strategic alliances, especially in China and US/EU

Results

- **2 US ANDAs**
- **11 co-development and cost/profit sharing products with various partners**

Strategic Alliance Highlights

* Already launched

Partner	Product	Indications	Region	Launch Year(E)	Remarks
Genovate	Entecavir	Hepatitis B Virus	Taiwan	2013*	1st co-developed formulation product launch
Sagent	Oncology Injectable	Myeloid Leukemia	US	2017	1st US ANDA filing, triggering US FDA inspection in Changshu, China site
Foresee	Leuprolide	Prostate cancer	US	2018	505(b)(2) NDA CRAM + Equity
Coland	Bortezomib	Multiple Myeloma	China	2020	1st co-developed drug in China to trigger CFDA inspection in Changshu site
	Azacitidine	MDS	China	2021	Co-developed formulation in China
Lee's Pharma	Fondaparinux	Anti-thrombotic	China	2021	Co-development collaboration
	Travoprost Bimatoprost	Glaucoma	China	2021	
Nanjing King Friend	Regadenoson	Stress agent for heart scan	China	2020	Co-developed formulation in China
US partner	Project A	Non-small cell lung cancer	US	2018	US NDA 505(b)(2) with Paragraph IV filing / The estimated launch year is subject to litigation results
US & China partners	Project B	Imaging agent	US	2021	ANDA with Paragraph IV filing / The estimated launch year is subject to litigation results

In-House Injectable Plant Progress and Outlook

- Taiwan-based facility will accommodate R&D, Quality Control, washing, sterilization, manufacturing, filling, lyophilization, packaging, and storage.
- Planned registration batch production by 2017. Expected to submit the first in-house ANDA in 2018 and pass US FDA inspection in 2019
- Target products with high entry barrier or unit-pricing as in peptides and oncology agents.
- Offering CMO services for both brand and proprietary drugs
- Nine drug products planned in the indications of cancer, diabetes, osteoporosis, multiple sclerosis, and anti-emesis


GETINGE

Aseptic Fill & Finish Service

Vial Product Line

Cytotoxic Injectable

Liquid Solution

Lyophilized Powder

Cartridge Product Line

Peptide Injectable

Prefilled-Syringe

Pen Device

ScinoPharm

Capturing Chinese Growth on Multiple Fronts

- MNCs and emerging virtual-model players create a sizable demand in high-quality and compliant API contract manufacturing in China.
- Existing review and approval mechanisms significantly raise the entry barrier and cost structure in the Chinese drug market, requiring dedication to quality and innovation.
- We have domestic presence plus world-class strength in:

  * Global, first-tier customer base
  * High-technical-barrier oncology APIs
  * Quality and EHS/GMP compliance

Strategic Goals in China

Short Term: Pass CFDA/EMA/EDQM inspections and expand CRAM services to diversified indications & processes to optimize portfolio and capacity utilization

Mid Term: Execute API+ANDA strategy by collaborating with formulators to apply for ANDA in US/EU/CN and share profits from drug product sales globally

Long Term: Expand into new delivery formulations and new drugs via strategic alliances, investments, and M&A

Selected List of CRAM Projects at Changshu

Customer	Project Type	Product Indication/stage	Product Type	Remarks/ Market
Top 10 global pharma	CMO	Approved antidepressant drug in US	GMP Intermediate	Passed Mexican authority (APIF) GMP inspection
Top 5 global pharma	CMO	Approved African sleeping disease drug	API	Site transfer from Taiwan
Lee's Pharma	CRO / CMO	>15 projects, including brain tumor, antibiotic, hypertension, eye drops, etc.	API	China
China pharm company	CRO	Phase II/ III clinical trial for cancer	API	China
China pharm company	CRO	Phase IIb for age-related macular degeneration	API	US/China
Taigen Biotech	CRO	Phase II clinical trial for myocardial infarction	API	China/Taiwan
US-based new drug company	CRO	Phase II clinical trial for prevention of HIV infection	API	US
Aslan Pharmaceuticals	CRO	Phase II clinical trial for cancer	API	China/Global
Top 5 global pharma	CRO	Phase III clinical trial for diabetes	Intermediate	US
Top 5 global pharma	CRO	Phase I clinical trial	API	NA
US NASDAQ listed pharma	CRO	Phase III clinical trial for opioid-induced constipation	Crude API	US
US-based new drug company	CRO	Phase I clinical trial for sickle cell disease	API	US

Operating Results & Outlook

Historical Performance

Unit: millions of NT$



ScinoPharm

Recent Financials

In NT$

Year	2013	2014	2015
Total assets	11,484 M	11,372 M	12,222 M
Shareholders' equity	9,643 M	9,380 M	9,857 M
Sales	5,088 M	4,098 M	3,955 M
Net profit after tax	1,273 M	484 M	635 M
Earnings per share	1.88	0.69	0.87
Cash dividends	1.2	0.2	0.3
Stock dividends	0.4	0.4	0.4
Pay-out ratio	85%	87%	80%

Note : All of the above figures represent consolidated information

ScinoPharm

2017 Product Launch Plan

Type	Product	Region	Indication	Brand Marketer	Regional Sales	WW Sales
API	Desmopressin Acetate	USA	Polyuria	Ferring	US$166M	US$405M
API	Tamsulosin HCl	USA	Benign Prostatic Hyperplasia (BPH)	Boehringer Ingelheim	US$333M	US$1706M
Generic Drug	Oncology Injectable	US	Myeloid Leukemia	MDS	US$183M	US$278M
CMO Project	Oral	USA EU	Antibiotics	N/A	N/A	N/A

Source: IMS Data (2015Q3-2016Q2)

Pipeline Outlook



Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT